Is 0QGH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0QGH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0QGH (€11.1) is trading above our estimate of fair value (€9.61)
Significantly Below Fair Value: 0QGH is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0QGH?
Key metric: As 0QGH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for 0QGH. This is calculated by dividing 0QGH's market cap by their current
revenue.
What is 0QGH's PS Ratio?
PS Ratio
1.3x
Sales
US$1.95b
Market Cap
US$2.50b
0QGH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: 0QGH is expensive based on its Price-To-Sales Ratio (1.3x) compared to the UK Chemicals industry average (1.3x).
Price to Sales Ratio vs Fair Ratio
What is 0QGH's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
0QGH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
1.3x
Fair PS Ratio
0.6x
Price-To-Sales vs Fair Ratio: 0QGH is expensive based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst 0QGH forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
€11.10
€18.26
+64.5%
46.1%
€35.11
€12.66
n/a
9
Nov ’25
€10.75
€24.25
+125.5%
40.9%
€35.31
€12.30
n/a
9
Oct ’25
€26.05
€31.75
+21.9%
6.0%
€34.23
€29.04
n/a
9
Sep ’25
€28.83
€31.27
+8.5%
6.8%
€34.19
€26.18
n/a
12
Aug ’25
€21.98
€30.75
+39.9%
11.5%
€38.20
€24.13
n/a
12
Jul ’25
€22.60
€29.86
+32.1%
14.0%
€37.95
€21.92
n/a
13
Jun ’25
€24.90
€29.94
+20.2%
13.8%
€37.76
€22.00
n/a
13
May ’25
€25.30
€30.45
+20.4%
15.7%
€38.71
€22.42
n/a
12
Apr ’25
€25.41
€30.18
+18.8%
14.9%
€37.88
€23.29
n/a
12
Mar ’25
€24.25
€30.60
+26.2%
14.9%
€38.29
€23.54
n/a
12
Feb ’25
€26.50
€28.57
+7.8%
17.4%
€38.17
€20.21
n/a
12
Jan ’25
€26.28
€26.46
+0.7%
16.4%
€37.57
€19.90
n/a
12
Dec ’24
€19.32
€26.82
+38.8%
16.5%
€37.89
€20.04
n/a
12
Nov ’24
€21.77
€30.33
+39.3%
17.3%
€42.08
€23.92
€10.75
12
Oct ’24
€26.42
€31.16
+17.9%
15.9%
€42.10
€24.85
€26.05
12
Sep ’24
€23.47
€30.99
+32.0%
21.5%
€47.21
€24.19
€28.83
13
Aug ’24
€25.82
€29.83
+15.5%
21.0%
€46.70
€23.03
€21.98
12
Jul ’24
€22.17
€31.92
+44.0%
21.0%
€46.19
€25.12
€22.60
12
Jun ’24
€20.49
€33.26
+62.3%
19.9%
€46.79
€25.45
€24.90
12
May ’24
€23.52
€35.03
+48.9%
17.1%
€45.76
€24.74
€25.30
11
Apr ’24
€31.27
€36.44
+16.6%
13.9%
€46.74
€29.80
€25.41
11
Mar ’24
€31.11
€36.98
+18.9%
11.8%
€43.70
€30.03
€24.25
10
Feb ’24
€31.25
€39.37
+26.0%
8.8%
€45.96
€32.84
€26.50
10
Jan ’24
€33.66
€42.25
+25.5%
9.3%
€48.13
€33.26
€26.28
10
Dec ’23
€39.94
€43.84
+9.8%
9.0%
€49.80
€34.41
€19.32
10
Nov ’23
€38.50
€44.83
+16.4%
9.5%
€52.05
€35.97
€21.77
10
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.